000130737 001__ 130737 000130737 005__ 20240201145617.0 000130737 0247_ $$2doi$$a10.1016/j.jpba.2016.02.033 000130737 0248_ $$2sideral$$a93999 000130737 037__ $$aART-2016-93999 000130737 041__ $$aeng 000130737 100__ $$0(orcid)0000-0003-1568-4591$$aCarrizo, D. 000130737 245__ $$aDirect screening of tobacco indicators in urine and saliva by Atmospheric Pressure Solid Analysis Probe coupled to quadrupole-time of flight mass spectrometry (ASAP-MS-Q-TOF-) 000130737 260__ $$c2016 000130737 5060_ $$aAccess copy available to the general public$$fUnrestricted 000130737 5203_ $$aA new screening method has been explored for direct analysis of tobacco smoke biomarkers in biological matrices (i.e., saliva and urine). Single run analysis using Atmospheric pressure Solid Analysis Probe (ASAP) and high resolution mass spectrometry with quadrupole and time of flight detector has been applied directly to some biological samples (i.e., urine and saliva), providing a fast, efficient and sensitive method of identification. The method has been applied to saliva and urine samples from heavy tobacco smokers for exposure studies. Nicotine itself, nicotine metabolites (i.e., cotinine, trans-3''-hydroxycotinine, nicotine-N-glucuronide) and other related tobacco smoke toxic compounds (i.e., NNK 4-methyl(nitroso)amino]-1-(3-pyridinyl)-1-butanone, anatabine) were found in the analyzed samples. The identification of compounds was confirmed by ultrahigh performance liquid chromatography with MS-triple quadrupole detector after sample treatment. Different temporal trends and biomarkers behavior have been found in time series related samples. Both methods are compared for screening of these biological matrices. 000130737 536__ $$9info:eu-repo/grantAgreement/ES/DGA/T10 000130737 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/ 000130737 590__ $$a3.255$$b2016 000130737 591__ $$aCHEMISTRY, ANALYTICAL$$b18 / 76 = 0.237$$c2016$$dQ1$$eT1 000130737 591__ $$aPHARMACOLOGY & PHARMACY$$b70 / 256 = 0.273$$c2016$$dQ2$$eT1 000130737 592__ $$a0.92$$b2016 000130737 593__ $$aPharmaceutical Science$$c2016$$dQ1 000130737 593__ $$aAnalytical Chemistry$$c2016$$dQ1 000130737 593__ $$aSpectroscopy$$c2016$$dQ2 000130737 593__ $$aClinical Biochemistry$$c2016$$dQ2 000130737 593__ $$aDrug Discovery$$c2016$$dQ2 000130737 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion 000130737 700__ $$0(orcid)0000-0001-6752-1992$$aNerín, I.$$uUniversidad de Zaragoza 000130737 700__ $$0(orcid)0000-0001-8893-0963$$aDomeño, C.$$uUniversidad de Zaragoza 000130737 700__ $$0(orcid)0000-0002-3703-7902$$aAlfaro, P.$$uUniversidad de Zaragoza 000130737 700__ $$0(orcid)0000-0003-2685-5739$$aNerín, C.$$uUniversidad de Zaragoza 000130737 7102_ $$12009$$2750$$aUniversidad de Zaragoza$$bDpto. Química Analítica$$cÁrea Química Analítica 000130737 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000130737 7102_ $$12009$$2X$$aUniversidad de Zaragoza$$bDpto. Química Analítica$$cProy. investigación HVA 000130737 773__ $$g124 (2016), 149-156$$pJ. pharm. biomed. anal.$$tJournal of Pharmaceutical and Biomedical Analysis$$x0731-7085 000130737 8564_ $$s1343050$$uhttps://zaguan.unizar.es/record/130737/files/texto_completo.pdf$$yPostprint 000130737 8564_ $$s1678929$$uhttps://zaguan.unizar.es/record/130737/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint 000130737 909CO $$ooai:zaguan.unizar.es:130737$$particulos$$pdriver 000130737 951__ $$a2024-02-01-14:51:53 000130737 980__ $$aARTICLE